UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1225-9
Program Prior Authorization/Notification
Medication Haegarda® (C1 esterase inhibitor Subcutaneous, human)
P&T Approval Date 8/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Haegarda is a plasma-derived concentrate of C1 esterase inhibitor (human) (C1-INH) indicated
for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of
age and older.1
2. Coverage Criteriaa:
A. Haegarda will be approved based on all of the following criteria:
1. Diagnosis of hereditary angioedema (HAE)
-AND-
2. For prophylaxis against HAE attacks
-AND-
3. Not used in combination with other products indicated for prophylaxis against HAE attacks
(e.g., Cinryze, Takhzyro, Orladeyo)
Authorization of therapy will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Haegarda [package insert]. Kankakee, IL: CSL Behring LLC.; January 2022.
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification – Haegarda (C1 esterase inhibitor
subcutaneous, human)
Change Control
8/2017 New program.
7/2018 Annual review. No changes to the coverage criteria. Updated
references.
7/2019 Annual review. No changes to the program.
7/2020 Annual review. No changes to coverage criteria. Updated background.
7/2021 Annual review. Updated combination use criteria to include all
prophylaxis agents. Updated references and background.
7/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote. Updated reference.
7/2023 Annual review. Revised wording of criteria without change to clinical
intent.
3/2024 Annual review. No changes to coverage criteria.
3/2025 Annual review. No changes to coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
2